» Articles » PMID: 32536012

5-Fluorouracil Resistance Mechanisms in Colorectal Cancer: From Classical Pathways to Promising Processes

Overview
Journal Cancer Sci
Specialty Oncology
Date 2020 Jun 15
PMID 32536012
Citations 198
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer (CRC) is a public health problem. It is the third most common cancer in the world, with nearly 1.8 million new cases diagnosed in 2018. The only curative treatment is surgery, especially for early tumor stages. When there is locoregional or distant invasion, chemotherapy can be introduced, in particular 5-fluorouracil (5-FU). However, the disease can become tolerant to these pharmaceutical treatments: resistance emerges, leading to early tumor recurrence. Different mechanisms can explain this 5-FU resistance. Some are disease-specific, whereas others, such as drug efflux, are evolutionarily conserved. These mechanisms are numerous and complex and can occur simultaneously in cells exposed to 5-FU. In this review, we construct a global outline of different mechanisms from disruption of 5-FU-metabolic enzymes and classic cellular processes (apoptosis, autophagy, glucose metabolism, oxidative stress, respiration, and cell cycle perturbation) to drug transporters and epithelial-mesenchymal transition induction. Particular interest is directed to tumor microenvironment function as well as epigenetic alterations and miRNA dysregulation, which are the more promising processes that will be the subject of much research in the future.

Citing Articles

Natural flavonoid Orientin restricts 5-Fluorouracil induced cancer stem cells mediated angiogenesis by regulating HIF1α and VEGFA in colorectal cancer.

Ghosh R, Bhowmik A, Biswas S, Samanta P, Sarkar R, Pakhira S Mol Med. 2025; 31(1):85.

PMID: 40045186 PMC: 11881437. DOI: 10.1186/s10020-024-01032-1.


Chemoresistance mechanisms to 5-Fluorouracil and reversal strategies in lung and breast cancer.

Zhong C, Wang S, Jiang W, Li Z, Wang X, Fan S Sci Rep. 2025; 15(1):6074.

PMID: 39972013 PMC: 11840071. DOI: 10.1038/s41598-025-90532-z.


Patient-Derived Tumor Organoids: A Platform for Precision Therapy of Colorectal Cancer.

Li Y, Wu W, Yao J, Wang S, Wu X, Yan J Cell Transplant. 2025; 34:9636897251314645.

PMID: 39953837 PMC: 11829288. DOI: 10.1177/09636897251314645.


Regulatory role of non-coding RNAs in 5-Fluorouracil resistance in gastrointestinal cancers.

Zhang H, Tang H, Tu W, Peng F Cancer Drug Resist. 2025; 8:4.

PMID: 39935428 PMC: 11810461. DOI: 10.20517/cdr.2024.167.


The impact of SEC23A on 5-FU chemotherapy sensitivity and its involvement in endoplasmic reticulum stress-induced apoptosis in colorectal cancer.

Su Z, Liu M, Krohn M, Schwarz S, Linnebacher M Apoptosis. 2025; .

PMID: 39904858 DOI: 10.1007/s10495-025-02084-2.


References
1.
Griffith M, Mwenifumbo J, Cheung P, Paul J, Pugh T, Tang M . Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-fluorouracil resistance in colorectal cancer. Pharmacogenomics J. 2012; 13(2):148-58. DOI: 10.1038/tpj.2011.65. View

2.
Zhang B, Leng C, Wu C, Zhang Z, Dou L, Luo X . Smad4 sensitizes colorectal cancer to 5-fluorouracil through cell cycle arrest by inhibiting the PI3K/Akt/CDC2/survivin cascade. Oncol Rep. 2015; 35(3):1807-15. DOI: 10.3892/or.2015.4479. View

3.
Cuezva J, Krajewska M, de Heredia M, Krajewski S, Santamaria G, Kim H . The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res. 2002; 62(22):6674-81. View

4.
Rasmussen K, Helin K . Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev. 2016; 30(7):733-50. PMC: 4826392. DOI: 10.1101/gad.276568.115. View

5.
Crea F, Nobili S, Paolicchi E, Perrone G, Napoli C, Landini I . Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist Updat. 2011; 14(6):280-96. DOI: 10.1016/j.drup.2011.08.001. View